Log in

Relevant bibliographies by topics / De7 .p52 2008 / Journal articles

To see the other types of publications on this topic, follow the link: De7 .p52 2008.

Journal articles on the topic 'De7 .p52 2008'

Author: Grafiati

Published: 25 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 38 journal articles for your research on the topic 'De7 .p52 2008.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kuczyk, M., J. Serth, C. Bokemeyer, et al. "Das P53-Tumorsuppressorgen: Möglicher Prognosefaktor für den klinischen Verlauf von Harnblasenkarzinomen?" Aktuelle Urologie 24, no. 06 (1993): 351–56. http://dx.doi.org/10.1055/s-2008-1058328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shu, Jihong. "Recombinant adenoviral human p53 gene combined with chemoradiotherapy in treatment of advanced unresectable head and neck cancer." Journal of Clinical Oncology 30, no. 15_suppl (2012): e16011-e16011. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e16011.

Full text

Abstract:

e16011 Background: In head and neck cancer, p53 mutations are present in up 60% of head and neck cancers. Studies indicated p53 gene could increase both radio- and chemo-sensitivities. In this study, we investigate the effectiveness of recombinant adenoviral human p53 gene (rAd-p53) combined with chemoradiotherapy in treatment of advanced unresectable head and neck cancer. Methods: From May 2008 to Dec. 2011, 48 patients with an advanced unresectable head and neck cancer, 29 males and 18 females with an average of 61.3 years old, were included this study. Those patients were treated with intra

APA, Harvard, Vancouver, ISO, and other styles

3

Srokowski, Cathy Cecilia, Joumana Masri, Nadine Hövelmeyer, et al. "Naturally occurring short splice variant of CYLD positively regulates dendritic cell function." Blood 113, no. 23 (2009): 5891–95. http://dx.doi.org/10.1182/blood-2008-08-175489.

Full text

Abstract:

Abstract Deubiquitination of NF-κB members by CYLD is crucial in controlling the magnitude and nature of cell activation. The role of the naturally occurring CYLD splice variant in dendritic cell (DC) function was analyzed using CYLDex7/8 mice, which lack the full-length CYLD (flCYLD) transcript and overexpress the short splice variant (sCYLD). Bone marrow–derived DCs from CYLDex7/8 mice display a hyperactive phenotype in vitro and in vivo and have a defect in establishing tolerance with the use of DEC-205–mediated antigen targeting to resting DCs. The combination of sCYLD overexpression and l

APA, Harvard, Vancouver, ISO, and other styles

4

Kuczyk, M., J. Serth, C. Bokemeyer, et al. "Häufigkeit von Alterationen des P53-Tumor-suppressorgens an Nierenzellkarzinomen und Korrelation mit dem klinischen Stadium." Aktuelle Urologie 26, S 1 (1995): 47–50. http://dx.doi.org/10.1055/s-2008-1057857.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Awan, Sohail M., Adnan Syed, and Shehzad Ghaffar. "p53 Protein Overexpression in Oral Squamous Cell Carcinomas." Otolaryngology–Head and Neck Surgery 139, no. 2_suppl (2008): P42. http://dx.doi.org/10.1016/j.otohns.2008.05.138.

Full text

Abstract:

Objective 1. To determine whether p53 protein expression is prognostic indicator of patient survival. 2. Learn its correlation with habits and histological variables of the tumor in Pakistani patients. Methods A retrospective case series of 140 patients with primary oral squamous cell carcinoma at a tertiary care setting during the period of January 1991 to Dec 2004. p53 protein overexpression was investigated by means of immunohistochemistry. Results of p53 overexpression were evaluated in relation to different clinicopathological parameters and survival. Overall survival and disease-free sur

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Zhong-guo. "Recombinant adeno-viral human p53 gene combined with FOLFOX4 in the treatment of advanced colorectal cancer." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14036-e14036. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14036.

Full text

Abstract:

e14036 Background: Metastatic or recurrent colorectal cancers generally become unresectable and will not respond to radio- or chemo-therapy. Studies showed that p53 has a synergic effect with radio- or chemotherapy. This study is to determine the efficacy and safety of recombinant adenoviral human p53 gene (rAd-p53) combined with standard FOLFOX4 regimen in treatment of advanced colorectal cancer. Methods: From July 2008 to Dec. 2011, 56 patients with an advanced colorectal cancer or local recurrent disease were treated with rAd-p53 and standard FOLFOX4 regimen. For local tumor, 1-4×1012 viral

APA, Harvard, Vancouver, ISO, and other styles

7

Álvarez-Ojeda, María G., César E. Guerrero-Gámez, Alberto Morales-Loredo, Yasmín I. Chew-Madinaveitia, Hazael Gutiérrez-Mauleón, and Omar G. Alvarado-Gómez. "DETECCIÓN POR RT-PCR DEL VIRUS DEL AMARILLAMIENTO Y ENANISMO EN CUCURBITÁCEAS (CYSDV) DEL CENTRO-NORTE DE MÉXICO." Revista Fitotecnia Mexicana 35, Especial_5 (2012): 43. http://dx.doi.org/10.35196/rfm.2012.especial_5.43.

Full text

Abstract:

Durante los años 2008 y 2009 se muestrearon plantas de melón (Cucumis melo L.), sandía (Citrullus lanatus Thumb), calabacita (Cucurbita pepo L.) y pepino (Cucumis sativus L.), así como especímenes de mosquita blanca (Bemisia tabaci Genn.) en diferentes localidades de los Estados de Nuevo León, Coahuila y Durango. Después de extraer el ARN, las muestras se analizaron con la técnica de RT-PCR, con oligonucleótidos específicos que amplifican regiones conservadas que codifican para las proteínas p22, de choque térmico y la cápside del virus del amarillamiento y enanismo de las cucurbitáceas (CYSDV

APA, Harvard, Vancouver, ISO, and other styles

8

Guo, Huiqin, Yu Zhao, Jiangyang Lu, David C. Christiani, Xihong Lin, and Zhaoxi Wang. "Extensive surgical resection in stage IV non-small cell lung cancer patients after tailored chemotherapy." Journal of Clinical Oncology 31, no. 15_suppl (2013): e19080-e19080. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19080.

Full text

Abstract:

e19080 Background: The treatment of stage IV non-small cell lung cancer patients is a problem for thoracic surgeons and the optimal treatment is discussed controversially. ERCC1, class III β-tubulin, p53, and RRM1 are predictive molecular biomarkers reported for neoadjuvant chemotherapy. Here we report a prospectively enrolled case series that patients were treated with extensive surgical resection after personalized chemotherapy tailored by these 4 markers. Methods: Patients with previously untreated stage IV NSCLC, ECOG PS of 0-2 were enrolled. The expression of ERCC1, class III β-tubulin, p

APA, Harvard, Vancouver, ISO, and other styles

9

Iype, Elizabeth Mathew, Lakshmi S, and Rajan Balakrishnan. "Selected molecular markers as indicators of clinical profile, tumor characteristics and treatment outcome in squamous cell carcinoma of the larynx." Journal of Clinical Oncology 37, no. 15_suppl (2019): e17522-e17522. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17522.

Full text

Abstract:

e17522 Background: Laryngeal Squamous cell carcinoma is widely prevalent in India and is the fourth leading cancer in males. The possibility that specific tumour characteristics (demonstrable by immunohistochemistry) may aid the clinician in choosing optimal treatments for a specific tumour, holds great promise. Objectives of the present study were to study the expression of select molecular markers p53, Bcl-2 (Apoptotic markers), EGFR, Ki67, Cyclin D1 (Proliferation markers) and Cox-2 (Inflammatory marker) in LSCC so as to form a hypothesis that a particular group of markers will be useful in

APA, Harvard, Vancouver, ISO, and other styles

10

List, Alan F., Kathy Rocha, Ling Zhang, et al. "Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression." Blood 114, no. 22 (2009): 292. http://dx.doi.org/10.1182/blood.v114.22.292.292.

Full text

Abstract:

Abstract Abstract 292 Background: Allelic deficiency for the RPS14 gene impairs differentiation and survival of erythroid progenitors in del(5q) MDS (Nature 2008; 451:335). Nucleolar stress arising from disruption of ribosome assembly fosters MDM2 sequestration by free ribosome components resulting in p53 stabilization and erythroid hypoplasia (Nat Cell Biol 2009; 11:501). We recently reported that reduced gene dosage of the lenalidomide (LEN) inhibitable, haplodeficient phosphatases CDC25C and PP2Acα is a key determinant of drug sensitivity in del(5q) MDS (PNAS 2009; 106: 12974). We now show

APA, Harvard, Vancouver, ISO, and other styles

11

Tarlock, Katherine, Todd A. Alonzo, Robert B. Gerbing, et al. "Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/DEK-NUP214 in Contemporary Trials with Intensification of Therapy: A Report from the Children's Oncology Group." Blood 138, Supplement 1 (2021): 519. http://dx.doi.org/10.1182/blood-2021-147576.

Full text

Abstract:

Abstract The occurrence of t(6;9)(p22;q34)/DEK-NUP214 is a rare subtype of pediatric AML that commonly co-occurs with FLT3-ITD mutations and is associated with poor outcomes, regardless of FLT3-ITD status. With increased recognition of the inferior prognostic impact of FLT3-ITD and to a lesser degree t(6;9), and with early identification of these lesions, these patients have been allocated to high risk intensive therapy on more contemporary clinical trials. Therefore we sought to interrogate the outcome of children with t(6;9) AML to determine if intensification of therapy, specifically the us

APA, Harvard, Vancouver, ISO, and other styles

12

Roth, A. D., S. Tejpar, P. Yan, et al. "Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 4022. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4022.

Full text

Abstract:

4022 Background and Aims: PETACC 3 is a large adjuvant trial with 3,005 COC pts. The value of BIOM in COC in adjuvant setting is still a matter of debate because of lack of large data sets. We took advantage of PETACC 3 to assess P53, SMAD4, thymidylate synthetase (TS), telomerase (HTERT) expressions, UGT1A1 genotype, KRAS and BRAF mutations, microsatellite instability (MSI), 18q and 8p LOH with regard to their prognostic and predictive value and their individual interactions on a very large homogeneous cohort of COC pts. In addition we investigated the association between UGT1A1 genotype and

APA, Harvard, Vancouver, ISO, and other styles

13

Bories, Pierre, Naïs Prade, Stéphanie Lagarde, et al. "TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine." Blood 132, Supplement 1 (2018): 2745. http://dx.doi.org/10.1182/blood-2018-99-117219.

Full text

Abstract:

Abstract Validated therapies for older pts with AML could rely on intensive or low-intensity strategies. Patient selection for these options remains controversial. There is currently no validated biomarker which can been used to guide therapeutic decision. TP53 mutations which are known to negatively impact AML pts outcome when treated with ICT, have been recently described as a positive prognosis factor for blast clearance with a 10-days regimen of decitabine (Welch, NEJM 2016). To date, it remains unclear whether AML pts with TP53 mutation represent a clinically homogeneous group. Several cl

APA, Harvard, Vancouver, ISO, and other styles

14

Lin, Thomas S., Nyla A. Heerema, Jennifer Swenor та ін. "A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities." Blood 104, № 11 (2004): 3469. http://dx.doi.org/10.1182/blood.v104.11.3469.3469.

Full text

Abstract:

Abstract The monoclonal anti-CD20 antibody rituximab (Rituxan) induces the death of chronic lymphocytic leukemia (CLL) cells in part through apoptosis. Tumor necrosis factor (TNF)-α and other cytokines up-regulate bcl-2 and other anti-apoptotic proteins, thereby inhibiting apoptosis. In addition, TNF-α may play a role in the cytokine release syndrome and infusion toxicity associated with monoclonal antibody therapy. Therefore, antagonists of TNF-α represent potential therapeutic agents that may be able to decrease infusion toxicity and enhance rituximab-induced apoptosis. We initiated a phase

APA, Harvard, Vancouver, ISO, and other styles

15

Ahmed, Bilal, Rima M. Saliba, Noman Ashraf, et al. "Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant." Blood 108, no. 11 (2006): 3101. http://dx.doi.org/10.1182/blood.v108.11.3101.3101.

Full text

Abstract:

Abstract Background: Chromosomal abnormalities detected by conventional cytogenetic analysis are known to adversely impact the outcome in myeloma patients. Abnormalities of chromosome 1, 13, 14 and 17 are commonly described. Deletions of the short arm of chromosome 1 presumably result in a loss of tumor suppressor genes, including p73, a member of the p53 family. We report the outcome of 83 myeloma patients with clonal cytogenetic abnormalities who underwent high-dose therapy and single autologous stem cell transplantation at our institution. Methods: We identified 83 patients (median age: 56

APA, Harvard, Vancouver, ISO, and other styles

16

Soares Lacerda, Wilian, and Paulo Fernando Seixas. "CONTROLE DE POSIÇÃO DE UMA MÁQUINA SÍNCRONA A ÍMÃS PERMANENTES." Revista Sinergia 2, no. 1 (2001): 56–63. http://dx.doi.org/10.33780/issn.2177-451x.2001.v2.n1.p56-63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sandahl, Julie Damgaard, Eva A. Coenen, Erik Forestier, et al. "Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study." Blood 120, no. 21 (2012): 538. http://dx.doi.org/10.1182/blood.v120.21.538.538.

Full text

Abstract:

Abstract Abstract 538 The cytogenetic subgroup t(6;9)(p22;q34), previously often reported as a breakpoint in 6p23, is defined as a distinct entity in the 2008 WHO classification of acute myeloid leukemia (AML). The translocation results in a chimeric fusion between DEK at 6p22.3 and NUP214 at 9q34.13 generating the DEK-NUP214 fusion gene. In adults, t(6;9) is associated with young age, very poor outcome, and a higher prevalence of FLT3-ITD than in any other type of AML. To date, the clinical impact of t(6;9) has not been independently described in a pediatric cohort. In this retrospective stud

APA, Harvard, Vancouver, ISO, and other styles

18

Gurney, Mark, Mrinal M. Patnaik, Curtis A. Hanson, et al. "The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities." Blood 128, no. 22 (2016): 5542. http://dx.doi.org/10.1182/blood.v128.22.5542.5542.

Full text

Abstract:

Abstract Background: 'Myelodysplastic syndrome (MDS) with isolated del(5q),' as defined by the World Health Organization (WHO) criteria (SwederlowSH, et al, 2008) is a unique pathological entity with favorable outcomes. The 2016 revision to the classification expands this entity to include cases that have an additional cytogenetic abnormality, with the exception of monosomy 7 or del(7q) (Arber DA, et al, Blood 2016). The objective of our study was to evaluate the prognostic impact of an additional cytogenetic abnormality, other than monosomy 7 or del(7q), in patients with 'MDS with isolated de

APA, Harvard, Vancouver, ISO, and other styles

19

d'Avila, Edson, and Ricardo Roberto Plaza Teixeira. "O DILEMA DA FORMAÇÃO PROFISSIONAL BÁSICA: A construção de um sistema de Qualificação Profissional Básica objetivando a formação do trabalhador-cidadão ou o treinamento rápido para reinserção no mercado de trabalho?" Revista Sinergia 2, no. 1 (2001): 25–30. http://dx.doi.org/10.33780/issn.2177-451x.2001.v2.n1.p25-30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Beatriz de Benedictis Delphino, Fátima. "MARCAS DE FALA NA ESCRITA: UMA VISÃO DO PORTUGUÊS DO BRASIL." Revista Sinergia 1, no. 1 (2000): 54–58. http://dx.doi.org/10.33780/issn.2177-451x.2000.v1.n1.p54-58.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Nishimura, Reiki, Tomofumi Osako, Yasuhiro Okumura, et al. "Abstract P4-07-12: An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer." Cancer Research 82, no. 4_Supplement (2022): P4–07–12—P4–07–12. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-07-12.

Full text

Abstract:

Abstract Background: Lymphovascular invasion (LVI) is associated with a poor outcome in breast cancer. The purpose of this study was to evaluate the clinical significance of LVI in primary breast cancer and to investigate disease-free survival (DFS) as a prognostic marker according to the breast cancer subtypes. The clinical significance of LVI was analyzed to investigate the biology and prognosis. Patients and Methods: This study examined 4,652 consecutive invasive breast cancer cases excluding the patients with non-invasive cancer, Stage IV and neo-adjuvant therapy from February 2002 to Febr

APA, Harvard, Vancouver, ISO, and other styles

22

Dumbrava, Ecaterina, Shivaani Kummar, Melissa Johnson, et al. "Abstract P3-12-27: Phase 1 Analysis from the PYNNACLE Phase 1/2 Study of Rezatapopt in the Subgroup of Patients with Advanced Breast Cancer Harboring a TP53 Y220C Mutation." Clinical Cancer Research 31, no. 12_Supplement (2025): P3–12–27—P3–12–27. https://doi.org/10.1158/1557-3265.sabcs24-p3-12-27.

Full text

Abstract:

Abstract Background: Mutations in the TP53 gene occur in ∼51% of breast cancers and result in loss of p53 tumor suppressor function and tumor progression. Reactivation of wild-type p53 is an attractive therapeutic approach for breast cancers with a TP53 mutation including the more aggressive triple-negative breast cancer (TNBC), where treatment options are limited. Rezatapopt (also known as PC14586) is an investigational first-in-class, p53 reactivator that selectively binds to the mutated p53 Y220C protein and stabilizes the structure in wild-type conformation, thereby restoring p53 wild-type

APA, Harvard, Vancouver, ISO, and other styles

23

Culver, Soluman, Nita Williams, Nidhi Sharma, et al. "Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival." Blood 128, no. 22 (2016): 4444. http://dx.doi.org/10.1182/blood.v128.22.4444.4444.

Full text

Abstract:

Abstract Introduction: Interphase FISH is used in the risk stratification of newly diagnosed multiple myeloma. The presence of high-risk cytogenetics is a key component of the Revised International Staging System (R-ISS), despite the fact that precise cutoffs for positivity have yet to be standardized and usage differs between institutions and reference labs. For deletion 17p, Avet-Loiseau et al (2007) used a 60% cutoff and An et al (2015) used 50% as a positive cutoff. For del(13q), Avet-Loiseau used del(13q14) 74% and An et al used 10%. Methods: Since 2011, consecutive patients in Ohio State

APA, Harvard, Vancouver, ISO, and other styles

24

Ghia, Emanuela M., Michael Y. Choi, George F. Widhopf II, and Thomas J. Kipps. "ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)." Blood 144, Supplement 1 (2024): 1852. https://doi.org/10.1182/blood-2024-211735.

Full text

Abstract:

ROR1 is a developmentally-restricted receptor for Wnt5a, which can induce ROR1-signaling leading to expression of target genes induced by activation of ERK1/2, NF-κB, or NRF2 in leukemia cells of patients (pts) with chronic lymphocytic leukemia (CLL). Prior work found that expression levels of ROR1, and expression levels of target genes induced by ROR1-signaling, vary between pts; furthermore, pts with CLL cells with high-level ROR1 (ROR1Hi) were found to have a significantly shorter median time from diagnosis until initial therapy and overall survival than pts with CLL cells with low-levels o

APA, Harvard, Vancouver, ISO, and other styles

25

Arima, Nobuyuki, Reiki Nishimura, Tomofumi Osako, et al. "Abstract P4-07-09: Triple negative breast cancer: An analysis of the subtypes and the effects of menopausal status on invasive breast cancer." Cancer Research 82, no. 4_Supplement (2022): P4–07–09—P4–07–09. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-07-09.

Full text

Abstract:

Abstract Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification, and is the most aggressive subtype with a heterogeneous genetic profile. Menopausal status is an important factor when considering endocrine therapy for patients with HR-positive tumors. Breast cancer in younger women can be more aggressive than in older women. Moreover, the menopausal status has limited predictive power for distant recurrence and overall survival (OS) in HR-positive cases. The aim of this retrospective study is to ev

APA, Harvard, Vancouver, ISO, and other styles

26

Chin, Melody, Jonathan Sive, Christopher Allen, et al. "Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival." Blood 128, no. 22 (2016): 4455. http://dx.doi.org/10.1182/blood.v128.22.4455.4455.

Full text

Abstract:

Abstract Background.The overall improvement in treatment outcomes and survival of multiple myeloma (MM) patients has highlighted the persistently poor outlook for patients with del(17p). Around a third of MM patients with del(17p) are also reported to have a TP53 mutation, while this mutation is rare in the absence of del(17p). The prognostic impact of TP53 mutations in the context of del(17p) is unresolved. We investigated the presence of TP53 mutations in a cohort of del(17p) patients to correlate mutation status with clinical outcome. We assessed the types of TP53 mutations, and the timing

APA, Harvard, Vancouver, ISO, and other styles

27

Daily, Avery, Julie Cupp, and Krystle Trosclair. "Abstract PO2-25-11: Incidence of Breast Cancer in Louisiana Compared to the United States." Cancer Research 84, no. 9_Supplement (2024): PO2–25–11—PO2–25–11. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-25-11.

Full text

Abstract:

Abstract Aside from skin cancer, breast cancer is the most common cancer in American women. More specifically, one in eight women will develop breast cancer during their lifetime. Breast cancer is classified into subtypes defined by immunohistochemistry (IHC) expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). ER+/PR+/HER2- tumors are the most common form of breast cancer and are typically associated with risk factors including older age, nulliparity, obesity following menopause, alcohol and tobacco use, sedentary lifestyle, an

APA, Harvard, Vancouver, ISO, and other styles

28

Chongxi, Ren, Sun Jianna, Kong Lingjun, and Hongjun Yu. "Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study." Cancer Research 84, no. 9_Supplement (2024): PO1–05–11—PO1–05–11. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-05-11.

Full text

Abstract:

Abstract Background: Metformin, an oral biguanide used for the treatment of type-2 diabetes mellitus (DM), has been shown in a considerable number of studies to have an anti-tumorigenic impact against breast cancer cells through several mechanisms,thereby improving breast cancer outcomes. However, the impact of metformin treatment on survival outcomes in patients with non-diabetic breast cancer is still under debate, with very few data available regarding metformin administration in de novo metastatic breast cancer (dnMBC). This study was conducted to investigate and evaluate the impact on sur

APA, Harvard, Vancouver, ISO, and other styles

29

Kaur, Navneet. "Abstract P5-04-12: Comparative Analysis of Female Breast Cancer: Incidence, Mortality, and 5-Year Survival Rates Across Races and Diagnosis Stages in Different Age Groups." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–04–12—P5–04–12. https://doi.org/10.1158/1557-3265.sabcs24-p5-04-12.

Full text

Abstract:

Abstract Background: Significant advancement has been made in breast cancer care, resulting in improved outcomes, largely due to enhanced screening and targeted management. However, these benefits are not equally distributed across all population subgroups. Factors such as genetics, access to healthcare, racial identity, social determinants of health, education, and clinical trial enrollment opportunities all contribute to persistent disparities in breast health. This study aims to compare female breast cancer incidence, mortality, and 5-year survival rates based on age, race, and stage at dia

APA, Harvard, Vancouver, ISO, and other styles

30

Garcia-Manero, Guillermo, Valeria Santini, Antonio Almeida, et al. "Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)." Blood 128, no. 22 (2016): 3190. http://dx.doi.org/10.1182/blood.v128.22.3190.3190.

Full text

Abstract:

Abstract Introduction: In the phase 3 MDS-005 study, LEN treatment was associated with a significant increase in transfusion independence (TI) vs placebo (26.9% vs 2.5%; P < 0.001) (Santini et al. J Clin Oncol. 2016;pii:JCO.2015.66.0118) and greater clinical benefit vs placebo (31.9% vs 3.8%) (Garcia-Manero et al. Haematologica. 2016;101:abstract P252) in red blood cell (RBC) transfusion-dependent (TD) pts with lower-risk non-del(5q) MDS who were ineligible for or refractory to erythropoiesis-stimulating agents (ESAs). For pts with lower-risk del(5q) MDS, a starting dose of LEN 10 mg is rec

APA, Harvard, Vancouver, ISO, and other styles

31

JPT staff, _. "E&P Notes (February 2021)." Journal of Petroleum Technology 73, no. 02 (2021): 20–22. http://dx.doi.org/10.2118/0221-0020-jpt.

Full text

Abstract:

Jersey Oil and Gas Unearths Wengen Prospect The Greater Buchan Area (GBA) now has four drill-ready prospects to add to discoveries already slated for development. In a new subsurface evaluation, Jersey Oil & Gas, a British-independent North Sea-focused upstream oil and gas company, has uncovered a new prospect, named Wengen, to complement its Verbier Deep, Cortina NE, and Zermatt drill-ready prospects. The four are estimated to host some 222 million bbl of P50 prospective resources, all in the immediate vicinity of Jersey’s planned GBA production facility. The consolidated Greater Buchan v

APA, Harvard, Vancouver, ISO, and other styles

32

Kuntzen, C., AL Gerbes, and ST Eichhorst. "Phosphoryliertes Jun inhibiert den CD95 Apoptosesignalweg unabhängig von p53 und p21." Zeitschrift für Gastroenterologie 42, no. 08 (2004). http://dx.doi.org/10.1055/s-2004-831780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hellweg, K., D. Scheunemann, M. Hoffmann, and G. Stefan. "Zusammenhang zwischen dem HPV-Status und dem Polymorphismus des p53 Tumorsuppressorgens in Codon 72 des Exon 4 bei Plattenepithelkarzinomen des Kopf-Hals-Bereiches." HNO-Informationen (Kongressabstracts) 84, no. 01 (2005). http://dx.doi.org/10.1055/s-2005-869146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

López, Alirio, Lesly Cerrato, Teynaldo Castro, Belinda Hasbun de Cadillo, and Jorge Carrasco. "Inmunorreactividad de la proteína p53 en lesiones premalignas y malignas del cérvix uterino." Revista Ciencia y Tecnología, February 7, 2015, 63–73. http://dx.doi.org/10.5377/rct.v0i7.1804.

Full text

Abstract:

Objetivo: Determinar la expresión p53 en las lesiones premalignas y malignas del cérvix en las pacientes de la consulta externa del servicio de Ginecología del Hospital Materno Infantil durante el período de julio de 2008 a diciembre de 2009. Material y métodos: Se realizó un estudio de tipo descriptivo transversal. Estudiándose una muestra de 90 pacientes de un universo de 209 pacientes. Las pacientes se caracterizaron según sus factores de riesgo además se tomó biopsia por colposcopia y/o conización a las pacientes con sospecha clínica de lesión premaligna o maligna del cérvix uterino. Las b

APA, Harvard, Vancouver, ISO, and other styles

35

"p53 Protocols (Deb, S., and Deb, S. P. (eds.) in Series “Methods in Molecular Biology”, Vol. 234 (Series Editor John Walker), Humana Press, 2003, 300 p., $89.50)." Biochemistry (Moscow) 69, no. 8 (2004): 934–35. http://dx.doi.org/10.1023/b:biry.0000040228.89036.46.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Olesen, O. J., N. E. Vinding, L. Oestergaard, et al. "P3798High levels of C-reactive protein after coronary artery bypass graft surgery is associated with postoperative atrial fibrillation." European Heart Journal 40, Supplement_1 (2019). http://dx.doi.org/10.1093/eurheartj/ehz745.0643.

Full text

Abstract:

Abstract Background Postoperative atrial fibrillation (POAF), a common complication following coronary artery bypass graft (CABG) surgery, is associated with increased morbidity and mortality. Inflammation seems to be an important pathogenic factor and elevated preoperative levels of C-reactive protein (CRP) are associated with POAF. However, the association between postoperative CRP and POAF is less established. Purpose To examine the association between postoperative levels of CRP and POAF after CABG. Methods Patients undergoing first-time isolated CABG (Jan 01, 2000 to Dec 31, 2016) were id

APA, Harvard, Vancouver, ISO, and other styles

37

Rajamanickam, Anitha, Yuan-Yuan Zhang, Claudine Jurkovitz, et al. "Abstract P54: Is Creatine Kinase-MB (CKMB) Really Necessary in the Diagnosis of Acute MI When Troponin Is Performed Simultaneously?" Circulation: Cardiovascular Quality and Outcomes 4, suppl_2 (2011). http://dx.doi.org/10.1161/circoutcomes.4.suppl_2.ap54.

Full text

Abstract:

BACKGROUND According to Joint ESC/ACC/AHA/WHF Task Force, troponin I (Tn) is the preferred biomarker for the diagnosis of acute MI. However, it is still common practice to order both serial CKMB and serial Tn to rule out acute MI. OBJECTIVE Our hypothesis is that most clinicians only use Tn and not the CKMB results in the diagnosis of acute MI when both test results are available. Subsequent investigation and management decisions are based on Tn and not on CKMB. METHODS Our large regional academic medical center has about 150,000 ED visits /yr. We queried the electronic medical records of 65,9

APA, Harvard, Vancouver, ISO, and other styles

38

Mohammed, SGHIAR, and LAKSSISSAR Ahmed. "Développement régional et efficience au Maroc : Analyse empirique." June 23, 2023. https://doi.org/10.5281/zenodo.8075932.

Full text

Abstract:

Le chantier de régionalisation avancée au Maroc vise essentiellement la réalisation d’un développement territorial intégré et durable et la réduction des disparités régionales. Depuis plusieurs années, l’État, les établissements publics et les collectivités territoriales ont mis en place des politiques et des programmes économiques et sociaux dans toutes les régions du Maroc visant en priorité la création de la richesse, la réduction de la pauvreté et

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!